Moderna (MRNA.US) is the best performing company in S&P 500 index today, gaining around 9% at press time. Gains were triggered by the announcement on the government trial website that the company is starting a mid-stage study of the experimental cancer vaccine in patients with cutaneous squamous carcinoma. Trial to test the vaccine will be in collaboration with Merck & Co (MRK.US). Results of a study on another Moderna-Merck vaccine showed in December 2023 reduce risk of severe skin cancer recurrence for three years.
Taking a look at Moderna (MRNA.US) chart at D1 interval, we can see that the stock surged today and climbed to the highest level since January 8, 2024. Share price is approaching a resistance zone in the $116 area, marked with previous local highs. A break above it would open the way towards the next major resistance zone to watch, which can be found in the $128.50 area.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile app
Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
